MY182353A - Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection - Google Patents

Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Info

Publication number
MY182353A
MY182353A MYPI2017704175A MYPI2017704175A MY182353A MY 182353 A MY182353 A MY 182353A MY PI2017704175 A MYPI2017704175 A MY PI2017704175A MY PI2017704175 A MYPI2017704175 A MY PI2017704175A MY 182353 A MY182353 A MY 182353A
Authority
MY
Malaysia
Prior art keywords
prophylaxis
derivatives
novel
treatment
virus infection
Prior art date
Application number
MYPI2017704175A
Other languages
English (en)
Inventor
Liang Chungen
Miao Kun
Wang Jianping
Yun Hongying
Zheng Xiufang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY182353(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY182353A publication Critical patent/MY182353A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2017704175A 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection MY182353A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
MY182353A true MY182353A (en) 2021-01-20

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017704175A MY182353A (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX393198B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych
EP3512556B1 (en) 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
JP7089596B2 (ja) * 2018-02-28 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための7位置換スルホンイミドイルプリノン化合物及び誘導体
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CA3128081A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US12503461B2 (en) 2019-09-20 2025-12-23 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2006242920A1 (en) * 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
CN110590809B (zh) 2013-03-29 2022-04-19 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Also Published As

Publication number Publication date
HUE045906T2 (hu) 2020-01-28
CL2017002745A1 (es) 2018-05-18
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
US20160326177A1 (en) 2016-11-10
SG10202108841YA (en) 2021-09-29
JP2018515509A (ja) 2018-06-14
HRP20191942T1 (hr) 2020-01-10
NZ775222A (en) 2024-09-27
SI3294740T1 (sl) 2019-12-31
PH12017502009A1 (en) 2018-03-26
AU2020256348B2 (en) 2022-06-16
MX2017014033A (es) 2018-03-01
WO2016180695A1 (en) 2016-11-17
JP6738352B2 (ja) 2020-08-12
BR112017023959B1 (pt) 2023-05-02
RU2017142577A3 (https=) 2019-10-31
CN107580596B (zh) 2020-07-14
ES2753777T3 (es) 2020-04-14
DK3294740T3 (da) 2019-11-04
TWI706954B (zh) 2020-10-11
AR104528A1 (es) 2017-07-26
US20170275286A1 (en) 2017-09-28
IL254947B (en) 2021-02-28
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
NZ735648A (en) 2023-06-30
PT3294740T (pt) 2019-10-29
AU2016260683B2 (en) 2020-10-29
RS59435B1 (sr) 2019-11-29
AU2022204666A1 (en) 2022-07-21
EP3294740A1 (en) 2018-03-21
MX2020010949A (es) 2022-06-16
PE20171620A1 (es) 2017-11-02
HK1247925A1 (zh) 2018-10-05
CA2982704A1 (en) 2016-11-17
KR20180003612A (ko) 2018-01-09
RU2017142577A (ru) 2019-06-10
AU2016260683A1 (en) 2017-10-12
US20200109144A1 (en) 2020-04-09
MX376761B (es) 2025-03-07
US10399983B2 (en) 2019-09-03
IL254947A0 (en) 2017-12-31
TW201716410A (zh) 2017-05-16
CN107580596A (zh) 2018-01-12
IL280769B2 (en) 2023-07-01
AU2020256348A1 (en) 2020-11-12
KR102690131B1 (ko) 2024-07-31
UA120450C2 (uk) 2019-12-10
CO2017009994A2 (es) 2018-02-20
US11242345B2 (en) 2022-02-08
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
IL280769B1 (en) 2023-03-01
CA2982704C (en) 2023-10-24
CR20170496A (es) 2017-12-05
MX393198B (es) 2025-03-19
IL280769A (en) 2021-04-29
EP3294740B1 (en) 2019-09-04
LT3294740T (lt) 2019-11-25

Similar Documents

Publication Publication Date Title
PH12019500432B1 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12017501258B1 (en) Pyrazine compounds for the treatment of infectious diseases
PH12017501061A1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12018500065A1 (en) Oxysterols and methods of use thereof
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MY188114A (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SG10201811384TA (en) Mnk inhibitors and methods related thereto
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX376283B (es) Compuestos de imidazopiridazina.
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.